Survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC): A real-world evidence study.

被引：3
|
作者：
Freedland, Stephen J. [1 ]
Sandin, Rickard [2 ]
Sah, Janvi [3 ]
Emir, Birol [4 ]
Mu, Qiao [3 ]
Ratiu, Anna [3 ]
Hong, Agnes [5 ]
Serfass, Lucile [6 ]
Tagawa, Scott T. [7 ]
机构：
[1] Vet Affairs Hlth Care Syst, Cedars Sinai Med Ctr, Dept Surg, Div Urol, Los Angeles, CA USA
[2] Pfizer AB, Sollentuna, Sweden
[3] STATinMED Res, Ann Arbor, MI USA
[4] Pfizer Inc, New York, NY USA
[5] Astellas Pharma Inc, Northbrook, IL USA
[6] Pfizer Inc, Paris, France
[7] New York Presbyterian Hosp, Weill Cornell Med Div Hematol & Med Oncol, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.46
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
46
引用
收藏
页数：2
相关论文
共 50 条
  • [31] The real-world efficacy of abiraterone acetate (ABA) and docetaxel (DOC) in the treatment of African-American (AA) patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC)
    Smith, Katherine E. R.
    Brown, Jacqueline T.
    Liu, Yuan
    LaFollette, Jennifer Ann
    Moore, Melvin R.
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [32] Outcomes of elderly patients (pts) treated with docetaxel (DOC) for metastatic castration-sensitive prostate cancer (mCSPC): Results from ECHOS, a multicenter Italian observational study.
    Caffo, Orazio
    Maruzzo, Marco
    Pravisano, Federico
    Buttigliero, Consuelo
    Soraru, Mariella
    Masini, Cristina
    Gori, Stefania
    Sabbatini, Roberto
    Pappalardo, Annalisa
    Cattrini, Carlo
    Fornarini, Giuseppe
    Vittimberga, Isabella
    Rametta, Alessandro
    Zucali, Paolo Andrea
    Fantinel, Emanuela
    Grillone, Francesco
    Fratino, Lucia
    Galli, Luca
    Giordano, Monica
    Basso, Umberto
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 153 - 153
  • [33] Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2010 to 2019
    George, D. J.
    Sandin, R.
    Agarwal, N.
    Tagawa, S. T.
    Klaassen, Z.
    Bitting, R.
    Ramaswamy, K.
    Emir, B.
    Bland, C.
    Hong, A.
    Shi, L.
    Yang, H.
    Gao, W.
    Song, W.
    Freedland, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1175 - S1176
  • [34] A cost-utility analysis of apalutamide for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
    Parmar, Ambika
    Timilshina, Narhari
    Emmenegger, Urban
    Alibhai, Shabbir M. H.
    Smoragiewicz, Martin
    Sander, Beate
    Chan, Kelvin K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2006 to 2019
    Freedland, S. J.
    Sandin, R.
    Tagawa, S. T.
    Klaassen, Z.
    Bitting, R. L.
    Ramaswamy, K.
    Emir, B.
    Bland, C.
    Hong, A.
    Yang, H.
    Gao, W.
    Song, W.
    George, D. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S650 - S651
  • [36] Impact of intensified androgen deprivation therapy (ADTi) in the metastatic castration-sensitive prostate cancer (mCSPC) setting on metastatic castration-resistant prostate cancer (mCRPC) disease characteristics and survival outcomes
    Tripathi, N.
    Gebrael, G.
    Sayegh, N.
    Goel, D.
    Brundage, J.
    Nordblad, B.
    Srivastava, A.
    Dal, E.
    Chehade, C. Hage
    Chigarira, B.
    Thomas, V. Mathew
    Sahu, K.
    Maughan, B. L.
    Agarwal, N.
    Swami, U.
    ANNALS OF ONCOLOGY, 2023, 34 : S973 - S973
  • [37] Use and outcomes in men with metastatic castration-sensitive prostate cancer (mCSPC) treated with docetaxel in addition to androgen deprivation therapy (ADT): Analysis of real-world data in the United States (US).
    Agarwal, Neeraj
    Mundle, Suneel
    Dearden, Lindsay
    Potluri, Ravi C.
    Nair, Sandhya
    Mehra, Maneesha
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [38] A Real-World Evidence Study Using Alberta-Population-Based Data to Describe Treatment Patterns for Metastatic Castration-Sensitive Prostate Cancer Patients (AWARENESS)
    Karim, Safiya
    Lowther, Jennifer
    Gyulay, Gabriel
    O'Sullivan, Dylan
    Wallis, Christopher J. D.
    Yip, Steven M.
    Brenner, Darren R.
    Boyne, Devon J.
    Cheung, Winson Y.
    CURRENT ONCOLOGY, 2023, 30 (09) : 8149 - 8158
  • [39] Prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC) initiated on apalutamide (APA) or abiraterone acetate (ABI) in real-world urology practices
    Brown, Gordon Andrew
    Khilfeh, Ibrahim
    Du, Shawn
    Rossi, Carmine
    Diaz, Lilian
    Kinkead, Frederic
    Muser, Erik
    Korsiak, Jill
    Lefebvre, Patrick
    Pilon, Dominic
    Ellis, Lorie
    Lowentritt, Benjamin H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 53 - 53
  • [40] Comparative survival in metastatic castration-sensitive prostate cancer (mCSPC) by prognostic subgroups: A living network meta-analysis
    Naqvi, Syed Arsalan Ahmed
    Bin Riaz, Irbaz
    Khakwani, Kaneez Zahra Rubab
    Bibi, Arifa
    Andrews, Jack R.
    Childs, Daniel S.
    Ravi, Praful
    Orme, Jacob
    Singh, Parminder
    Sweeney, Christopher
    Bryce, Alan Haruo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 171 - 171
12345